Dr Jessica Lee

Jessica is research lead of the Concord Centre for Palliative Care and provides input into the overall Sydney Catalyst program via the T2/T3 Working Group by contributing to the generation of new ideas, recommendations for capacity building and advocating for the interests of members working in the evidence into practice space.
ROLE
  • T2/T3 Working Group

Background:  

Jessica is a palliative medicine physician and clinician-researcher at the Concord Centre for Palliative Care. She is a PhD candidate at University of Technology, Sydney, studying how to improve outcomes in neuropathic cancer pain with a focus on implementation ready translational outcomes from clinical trials and implementation of evidence into practice.

She leads the Concord Palliative Care Research Group which is involved in numerous phase II, III and IV investigator initiated clinical trials.

She is an executive member of Improving Palliative Care in Clinical Trials (the NSW palliative care research collaborative) and is building a community of practice for early career clinician researchers working in a supportive care space. She is the pain symptom node lead and trials management committee member of the Palliative Care Clinical Studies Collaborative (the Australian palliative care research collaborative).

With the help of her wonderful family, Jessica juggles research and clinical practice with being a working mum to a joyful toddler

Research Interests:  

Jessica is passionate about building a strong culture of research and evidence based practice to improve care of patients with advanced illness. She believes patient centered care and holistic care are cornerstones of best practice.   

She is currently leading research in neuropathic cancer pain, randomised controlled trial of lignocaine infusion for neuropathic cancer pain, developing a customisable multi-lingual patient communication tool and multi-disciplinary management of refractory breathlessness. She is interested in all aspects of translational research involving palliative care patients.